Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells

Fig. 4

Comparison between possible past DENV infection in pre-exposure group vs. patient group for neutralizing antibody titer and fold enhancement. a & c: Non patient 1 = serum samples from pre-exposure group with possible infecting serotype of DENV-2 (based on the highest N.A titer reacts to DENV-2); Patient = serum samples from patient group with infecting serotype of DENV-2 (virology confirmation). b & d: Non patient 1 = serum samples from pre-exposure group with possible infecting serotype of DENV-3 (based on the highest N.A titer reacts to DENV-3); Patient = serum samples from patient group with infecting serotype of DENV3 (virology confirm). Fold enhancement value was determined by the ratio of (mean plaque count at 1:20 serum dilution)/(mean plaque count in the absence of human serum samples) by using FcγR-expressing BHK cells. Dash line represents for cut-off plus 2 times SD value of infection-enhancement. Positive infection-enhancing activity was defined as fold enhancement value greater than cut-off value plus 2 times SD (above dash line). P-value was determined by Mann-Whitney test. P-value ≤0.05 = significant. The results were represented as Median ± interquartile range (Median ± IQR)

Back to article page